KZR VS ASXC Stock Comparison
Performance
KZR10/100
10/100
KZR returned -90.12% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
ASXC10/100
10/100
ASXC returned -49.79% in the last 12 months. Based on SPY's performance of -13.09%, its performance is below average giving it a score of 10 of 100.
Analyst Price Targets
KZR94/100
94/100
4 analysts offer 12-month price targets for KZR. Together, they have an average target of 17.5, the most optimistic target put KZR at 21 within 12-months and the most pessimistic has KZR at 14.
ASXC
"Analyst Price Targets" not found for ASXC
Sentiment
KZR71/100
71/100
KZR had a bullish sentiment score of 71.02% across Twitter and StockTwits over the last 12 months. It had an average of 2.88 posts, 0.88 comments, and 0.62 likes per day.
ASXC
"Sentiment" not found for ASXC
Technicals
KZR29/100
29/100
KZR receives a 28 of 100 based on 14 indicators. 3 are bullish, 9 are bearish.
ASXC50/100
50/100
ASXC receives a 50 of 100 based on 14 indicators. 6 are bullish, 6 are bearish.
Earnings
KZR10/100
10/100
KZR has missed earnings 6 times in the last 20 quarters.
ASXC20/100
20/100
ASXC has missed earnings 4 times in the last 20 quarters.
Profit
KZR10/100
10/100
Out of the last 20 quarters, KZR has had 0 profitable quarters and has increased their profits year over year on 0 of them.
ASXC10/100
10/100
Out of the last 20 quarters, ASXC has had 0 profitable quarters and has increased their profits year over year on 1 of them.
Volatility
KZR41/100
41/100
KZR has had a lower than average amount of volatility over the last 12 months giving it a score of 40 of 100.
ASXC49/100
49/100
ASXC has had a lower than average amount of volatility over the last 12 months giving it a score of 49 of 100.
All score calculations are broken down here to help you make more informed investing decisions
Kezar Life Sciences, Inc. Common Stock Summary
Nasdaq / KZR
Healthcare
Biotechnology
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California.
Asensus Surgical, Inc. Summary
Healthcare
Medical - Devices
Asensus Surgical, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery (MIS) in the United States, Europe, and Asia. It digitizes the interface between the surgeon and the patient to pioneer a new era of Performance-Guided surgery by unlocking clinical intelligence for surgeons to enable consistently superior outcomes and a new standard of surgery. The company's products include Senhance Surgical system, a multi-port robotic surgery system that allows up to four arms to control robotic instruments and a camera for laparoscopic procedures. Its products also comprise instruments and other products, including 3mm diameter instruments, 3mm and 5mm hooks, and articulating instruments; and Senhance ultrasonic system, an advanced energy device to deliver controlled energy to ligate and divide tissue. The company was formerly known as TransEnterix, Inc. and changed its name to Asensus Surgical, Inc. in February 2021. Asensus Surgical, Inc. was founded in 2006 and is headquartered in Durham, North Carolina.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare KZR to other companies in the same or a similar industry.